PBAC's latest decision on Levodopa with carbidopa monohydrate: Recommended with restriction (2019). Considered for Advanced Parkinson's disease with severe disabling motor fluctuations not adequately controlled by oral therapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Patients with advanced Parkinson's disease who have severe disabling motor fluctuations not adequately controlled by oral therapy, commenced on treatment in a hospital-based movement disorder clinic, with adequate cognitive function to manage administration with a portable continuous infusion pump.
Therapy area
Neurology
Line of therapy
Not applicable
Evidence base
Other
Economic model
Not modelled
ICER note
Not modelled — this is a minor submission (reformulation/maximum quantity adjustment) with no new economic evaluation.
Risk sharing
Risk-sharing arrangement in place — Duodopa is subject to a Deed of Agreement which encompasses a Special Pricing Arrangement (SPA) rebate and a Risk Sharing Arrangement (RSA) with subsidisation caps.